They will also be accountable for the effective interface and influential stakeholder management between UCB, Phase 1 Units, Clinical Research Organizations (CROs) and other vendors to ensure assigned studies are delivered according to contract specifications, with high quality, meeting all major milestones and to budget. Demonstrate robust oversight of sponsor-delegated activities by regularly reviewing CRO/Phase 1 Unit performance, including TMF status, through use of KPIs, metrics and deliverables (such as SQV, Impact), with a focus on trial subject safety, data quality, and critical activities that might delay the project or impact budget.